Norges Bank purchased a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,000,000 shares of the company's stock, valued at approximately $16,440,000. Norges Bank owned approximately 1.87% of Upstream Bio at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. US Bancorp DE bought a new position in Upstream Bio during the fourth quarter valued at about $27,000. Corebridge Financial Inc. bought a new stake in shares of Upstream Bio in the 4th quarter worth approximately $142,000. Rhumbline Advisers bought a new stake in shares of Upstream Bio in the 4th quarter worth approximately $275,000. Bank of New York Mellon Corp acquired a new stake in Upstream Bio during the fourth quarter valued at approximately $607,000. Finally, JPMorgan Chase & Co. bought a new stake in Upstream Bio during the fourth quarter worth approximately $786,000.
Upstream Bio Stock Performance
Shares of NASDAQ UPB traded up $0.97 during trading on Friday, hitting $7.37. The company had a trading volume of 303,708 shares, compared to its average volume of 327,123. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46. The firm has a 50-day moving average of $7.68.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
